I am actually hoping that Acadia gives us mediocre results this week. (It will create a new buying opportunity).
I believe that NNZ2591 is the "superior drug" and that inevitably - NNZ2591 should be used for Retts and Fragile-X in addition to the four ailments we are currently trialling and much much more. So far, there are little or no side effects when using NNZ2591 and it appears to be at least as effective as trofinetide.
This (NNZ2591) is the jewel in the crown for Neuren - trofinetide and Acadia are just the stepping stones, still with a lot of spring in them to go yet.
I am actually hoping that Acadia gives us mediocre results this...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.30 |
Change
0.760(4.59%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.35 | $17.94 | $17.25 | $17.64M | 1.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2533 | $17.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.45 | 1254 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |